Ambrx Biopharma Cash on Hand 2020-2021 | AMAM
Ambrx Biopharma cash on hand from 2020 to 2021. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Ambrx Biopharma Annual Cash on Hand (Millions of US $) |
2021 |
$171 |
2020 |
$91 |
2019 |
$16 |
Ambrx Biopharma Quarterly Cash on Hand (Millions of US $) |
2021-12-31 |
$171 |
2020-12-31 |
$91 |
2019-12-31 |
$16 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.149B |
$0.007B |
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
|